Ziccum AB (publ) has signed a Material Transfer and Evaluation Agreement for a Vaccine Evaluation project with one of the most important technology-focused Biomanufacturing corporations in the US. The project is funded and will focus on evaluating the potential for new dry, thermostable forms of an advanced viral vaccine, using Ziccum's unique formulation and drying technology LaminarPace. Ziccum has signed three agreements for funded partner studies since May 2023, and these add up to combined revenues of SEK 10 MSEK.

The new agreement is the third major partner contract for funded Feasibility studies that Ziccum has signed in recent months. It significantly broadens the company's strategic and biotherapeutic position. Strategically, it is the first agreement for the company with a Biomanufacturing corporation- a vital industry segment in vaccine manufacturing.

The project aims to evaluate Ziccum's unique formulations, LaminarPace, for treatment of an advanced viral vaccine material. The material belongs to one of the three high-potential vaccine platforms that Ziccum targets and has worked on in-house. If successful, the project will represent a significant step forward in demonstrating LaminarPace's potential across markets and modalities.